Talal Hilal1, Jeffrey A Betcher2, Jose F Leis3. 1. Division of Hematology and Medical Oncology, Mayo Clinic, 5881 E. Mayo Blvd, Phoenix, AZ, 85054, USA. 2. Department of Pharmacy, Mayo Clinic, Phoenix, AZ, USA. 3. Division of Hematology and Medical Oncology, Mayo Clinic, 5881 E. Mayo Blvd, Phoenix, AZ, 85054, USA. leis.jose@mayo.edu.
Abstract
PURPOSE OF REVIEW: Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices. RECENT FINDINGS: The cost of therapy for CLL has increased substantially since the introduction of oral therapies. This increase in cost is caused by multiple factors including cost of drug development, alternate reimbursement patterns, lack of transparency, and lack of free market competition. Oral therapies for CLL have dramatically increased costs for both patients and payers. Some solutions to overcome this include value-based pricing, transparency, and legal action that allow Medicare to negotiate drug prices with manufacturers.
PURPOSE OF REVIEW: Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices. RECENT FINDINGS: The cost of therapy for CLL has increased substantially since the introduction of oral therapies. This increase in cost is caused by multiple factors including cost of drug development, alternate reimbursement patterns, lack of transparency, and lack of free market competition. Oral therapies for CLL have dramatically increased costs for both patients and payers. Some solutions to overcome this include value-based pricing, transparency, and legal action that allow Medicare to negotiate drug prices with manufacturers.
Entities:
Keywords:
CLL; Drug costs; Ibrutinib; Idelalisib; Pharmacoeconomics, financial toxicity; Venetoclax
Authors: Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles Journal: N Engl J Med Date: 2014-01-22 Impact factor: 91.245
Authors: G Dighiero; K Maloum; B Desablens; B Cazin; M Navarro; R Leblay; M Leporrier; J Jaubert; G Lepeu; B Dreyfus; J L Binet; P Travade Journal: N Engl J Med Date: 1998-05-21 Impact factor: 91.245
Authors: Rositsa Koleva-Kolarova; James Buchanan; Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; Maureen Rutten-van Mölken; László Szilberhorn; Tamás Zelei; Balázs Nagy; Sarah Wordsworth; Apostolos Tsiachristas Journal: Appl Health Econ Health Policy Date: 2022-04-04 Impact factor: 3.686
Authors: Chan Shen; Rolfy A Perez Holguin; Eric Schaefer; Shouhao Zhou; Chandra P Belani; Patrick C Ma; Michael F Reed Journal: BMC Health Serv Res Date: 2022-04-09 Impact factor: 2.655